SLC1A5 and colonic neoplasm: Targeting glutamine transporter SLC1A5 in breast and colon cancer can inhibit the exogenous uptake of glutamine and serve the purpose of “starving” tumor cells.[32] But our findings suggest that blockade of glutamine uptake would not be sufficient to starve cancer cells of glutamine, since glutamine starvation can activate GS‐mediated glutamine biosynthesis, which is conducive to stemness maintenance of cancer cells.